The goal of this clinical research study is to learn the effects of the standard dose of erlotinib and the higher dose of erlotinib on biomarker levels in patients with head and neck cancer. Biomarkers are chemical "markers" in the blood and/or tissue that may be related to your response to the study drug. The safety of the drug will also be studied.